Large BRCA1 and BRCA2 Genomic Rearrangements in Polish High-risk Breast and Ovarian Cancer Families

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2013 Sep 26

PMID 24065545

Citations 10

Authors

Helena Rudnicka

Tadeusz Debniak

Cezary Cybulski

Tomasz Huzarski

Jacek Gronwald

Jan Lubinski

Bohdan Gorski

Affiliations

Soon will be listed here.

Abstract

BRCA1 and BRCA2 are two major genes associated with familial breast and ovarian cancer susceptibility. In Poland standard BRCA gene test is usually limited to Polish founder BRCA1 mutations: 5382insC, C61G and 4153delA. To date, just a few single large genomic rearrangements (LGRs) of BRCA1 gene have been reported in Poland. Here we report the first comprehensive analysis of large mutations in BRCA1 and BRCA2 genes in this country. We screened LGRs in BRCA1 and BRCA2 genes by multiplex ligation-dependent probe amplification in 200 unrelated patients with strong family history of breast/ovarian cancers and negative for BRCA1 Polish founder mutations. We identified three different LGRs in BRCA1 gene: exons 13-19 deletion, exon 17 deletion and exon 22 deletion. No LGR was detected in BRCA2 genes. Overall, large rearrangements accounted for 3.7 % of all BRCA1 mutation positive families in our population and 1.5 % in high-risk families negative for Polish founder mutation.

Citing Articles

Comprehensive profiling of pathogenic germline large genomic rearrangements in a pan-cancer analysis.

Sun Z, Bai C, Su M, Tang H, Wu X, Wang Y Mol Oncol. 2023; 17(9):1917-1929.

PMID: 37013911 PMC: 10483597. DOI: 10.1002/1878-0261.13430.

Germline Structural Variations in Cancer Predisposition Genes.

Pocza T, Grolmusz V, Papp J, Butz H, Patocs A, Bozsik A Front Genet. 2021; 12:634217.

PMID: 33936164 PMC: 8081352. DOI: 10.3389/fgene.2021.634217.

Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing.

Szczerba E, Kaminska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska M Genes (Basel). 2021; 12(4).

PMID: 33918338 PMC: 8065856. DOI: 10.3390/genes12040519.

Complex Characterization of Germline Large Genomic Rearrangements of the and Genes in High-Risk Breast Cancer Patients-Novel Variants from a Large National Center.

Bozsik A, Pocza T, Papp J, Vaszko T, Butz H, Patocs A Int J Mol Sci. 2020; 21(13).

PMID: 32629901 PMC: 7370166. DOI: 10.3390/ijms21134650.

Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.

Park B, Sohn J, Yoon K, Lee K, Cho E, Lim M Breast Cancer Res Treat. 2017; 163(1):139-150.

PMID: 28205045 PMC: 5387004. DOI: 10.1007/s10549-017-4142-7.

References

Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S . Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Fam Cancer. 2008; 8(2):127-33. DOI: 10.1007/s10689-008-9216-6. View

Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

Woodward A, Davis T, Silva A, Kirk J, Leary J . Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet. 2005; 42(5):e31. PMC: 1736061. DOI: 10.1136/jmg.2004.027961. View

Peelen T, van Vliet M, Bosch A, Bignell G, Vasen H, Klijn J . Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer. 2000; 82(1):151-6. PMC: 2363204. DOI: 10.1054/bjoc.1999.0892. View

Nordling M, Karlsson P, Wahlstrom J, Engwall Y, Wallgren A, Martinsson T . A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res. 1998; 58(7):1372-5. View

Grzybowska E, Zientek H, Jasinska A, Rusin M, Kozlowski P, Sobczak K . High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum Mutat. 2000; 16(6):482-90. DOI: 10.1002/1098-1004(200012)16:6<482::AID-HUMU5>3.0.CO;2-O. View

Vasickova P, Machackova E, Lukesova M, Damborsky J, Horky O, Pavlu H . High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet. 2007; 8:32. PMC: 1904436. DOI: 10.1186/1471-2350-8-32. View

Jakubowska A, Gorski B, Byrski T, Huzarski T, Gronwald J, Menkiszak J . Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. Hum Mutat. 2001; 18(2):149-56. DOI: 10.1002/humu.1164. View

Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst F . BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997; 17(3):341-5. DOI: 10.1038/ng1197-341. View

10.

Agata S, Viel A, Puppa L, Cortesi L, Fersini G, Callegaro M . Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. Genes Chromosomes Cancer. 2006; 45(9):791-7. DOI: 10.1002/gcc.20342. View

11.

Hendrickson B, Judkins T, Ward B, Eliason K, Deffenbaugh A, Burbidge L . Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer. 2005; 43(3):309-13. DOI: 10.1002/gcc.20189. View

12.

Schouten J, McElgunn C, Waaijer R, Zwijnenburg D, Diepvens F, Pals G . Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30(12):e57. PMC: 117299. DOI: 10.1093/nar/gnf056. View

13.

Gutierrez-Enriquez S, de la Hoya M, Martinez-Bouzas C, Sanchez de Abajo A, Ramon Y Cajal T, Llort G . Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat. 2006; 103(1):103-7. DOI: 10.1007/s10549-006-9376-8. View

14.

Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M . Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Breast Cancer Res Treat. 2010; 124(2):337-47. DOI: 10.1007/s10549-010-0745-y. View

15.

Puget N, Torchard D, Lynch H, Feunteun J, Lenoir G, Mazoyer S . A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997; 57(5):828-31. View

16.

den Dunnen J, Antonarakis S . Nomenclature for the description of human sequence variations. Hum Genet. 2001; 109(1):121-4. DOI: 10.1007/s004390100505. View

17.

Sluiter M, van Rensburg E . Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. 2010; 125(2):325-49. DOI: 10.1007/s10549-010-0817-z. View

18.

Thomassen M, Gerdes A, Cruger D, Jensen P, Kruse T . Low frequency of large genomic rearrangements of BRCA1 and BRCA2 in western Denmark. Cancer Genet Cytogenet. 2006; 168(2):168-71. DOI: 10.1016/j.cancergencyto.2005.12.016. View

19.

Peixoto A, Santos C, Rocha P, Pinheiro M, Principe S, Pereira D . The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat. 2008; 114(1):31-8. DOI: 10.1007/s10549-008-9978-4. View

20.

Montagna M, Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L . Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003; 12(9):1055-61. DOI: 10.1093/hmg/ddg120. View